Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2018
This article has no abstract
Epistemonikos ID: 22723fba3e5c5be4a0fd517a41dbd069cc227ba8
First added on: Apr 17, 2025